{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:51:36Z","timestamp":1782309096527,"version":"3.54.5"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,24]]},"DOI":"10.7759\/cureus.111423","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:37:21Z","timestamp":1782308241000},"source":"Crossref","is-referenced-by-count":0,"title":["Association of sTREM2 and YKL-40 With Alzheimer\u2019s Disease Progression: A Systematic Review"],"prefix":"10.7759","author":[{"given":"Rasha Omer","family":"Babiker Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubaker M","family":"Elamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Salim","family":"Ali Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma  B","family":"Mahmuod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hounayda Abdelrahman","family":"Mohamed Hamid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawan Awad Amer","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May Medhat","family":"Aboaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global Status Report on the Public Health Response to Dementia. (2021). Accessed. May 13, 2026: https:\/\/www.who.int\/publications\/i\/item\/9789240033245."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.320970","article-title":"Pathological mechanisms and therapeutic strategies for Alzheimer's disease","volume":"17","author":"Ju Y","year":"2022","unstructured":"Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer's disease. Neural Regen Res. 2022, 17:543-9. 10.4103\/1673-5374.320970","journal-title":"Neural Regen Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.109","article-title":"Neuroinflammation, its role in Alzheimer's disease and therapeutic strategies","volume":"10","author":"Kiraly M","year":"2023","unstructured":"Kiraly M, Foss JF, Giordano T. Neuroinflammation, its role in Alzheimer's disease and therapeutic strategies. J Prev Alzheimers Dis. 2023, 10:686-98. 10.14283\/jpad.2023.109","journal-title":"J Prev Alzheimers Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0184-x","article-title":"Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk","volume":"12","author":"Efthymiou AG","year":"2017","unstructured":"Efthymiou AG, Goate AM. Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk. Mol Neurodegener. 2017, 12:43. 10.1186\/s13024-017-0184-x","journal-title":"Mol Neurodegener"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03986-5","article-title":"Genomics of Alzheimer's disease implicates the innate and adaptive immune systems","volume":"78","author":"Li Y","year":"2021","unstructured":"Li Y, Laws SM, Miles LA, Wiley JS, Huang X, Masters CL, Gu BJ. Genomics of Alzheimer's disease implicates the innate and adaptive immune systems. Cell Mol Life Sci. 2021, 78:7397-426. 10.1007\/s00018-021-03986-5","journal-title":"Cell Mol Life Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12612","article-title":"Potential role of chitinase-3-like protein 1 (CHI3L1\/YKL-40) in neurodegeneration and Alzheimer's disease","volume":"19","author":"Connolly K","year":"2023","unstructured":"Connolly K, Lehoux M, O'Rourke R, et al.. Potential role of chitinase-3-like protein 1 (CHI3L1\/YKL-40) in neurodegeneration and Alzheimer's disease. Alzheimers Dement. 2023, 19:9-24. 10.1002\/alz.12612","journal-title":"Alzheimers Dement"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/nrn.2016.7","article-title":"TREM2 variants: new keys to decipher Alzheimer disease pathogenesis","volume":"17","author":"Colonna M","year":"2016","unstructured":"Colonna M, Wang Y. TREM2 variants: new keys to decipher Alzheimer disease pathogenesis. Nat Rev Neurosci. 2016, 17:201-7. 10.1038\/nrn.2016.7","journal-title":"Nat Rev Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-020-01878-2","article-title":"TREM2 ectodomain and its soluble form in Alzheimer's disease","volume":"17","author":"Yang J","year":"2020","unstructured":"Yang J, Fu Z, Zhang X, Xiong M, Meng L, Zhang Z. TREM2 ectodomain and its soluble form in Alzheimer's disease. J Neuroinflammation. 2020, 17:204. 10.1186\/s12974-020-01878-2","journal-title":"J Neuroinflammation"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-019-03040-5","article-title":"Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis","volume":"76","author":"Dhiman K","year":"2019","unstructured":"Dhiman K, Blennow K, Zetterberg H, Martins RN, Gupta VB. Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. Cell Mol Life Sci. 2019, 76:1833-63. 10.1007\/s00018-019-03040-5","journal-title":"Cell Mol Life Sci"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-8060930\/v1","article-title":"Neuroinflammatory markers sTREM2 and YKL-40 in association with Alzheimer\u2019s disease pathology: a systematic review and meta-analysis [PREPRINT]","author":"Yu R","year":"2025","unstructured":"Yu R, Suraev A, Vidal V, et al.. Neuroinflammatory markers sTREM2 and YKL-40 in association with Alzheimer\u2019s disease pathology: a systematic review and meta-analysis [PREPRINT]. Research Square. 2025, 10.21203\/rs.3.rs-8060930\/v1","journal-title":"Research Square"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-014-0579-0","article-title":"PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews","volume":"14","author":"Methley AM","year":"2014","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014, 14:579. 10.1186\/s12913-014-0579-0","journal-title":"BMC Health Serv Res"},{"key":"ref13","unstructured":"The Newcastle-Ottawa Scale (Nos) for Assessing the Quality of Non-randomised Studies in Meta-Analyses. (2000). https.\/\/ohri.ca\/en\/who-we-are\/core-facilities-and-platforms\/ottawa-methods-centre\/newcastle-ottawa-scale."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202216987","article-title":"sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease","volume":"15","author":"Biel D","year":"2023","unstructured":"Biel D, Su\u00e1rez-Calvet M, Hager P, et al.. sTREM2 is associated with amyloid-related p-tau increases and glucose hypermetabolism in Alzheimer's disease. EMBO Mol Med. 2023, 15:e16987. 10.15252\/emmm.202216987","journal-title":"EMBO Mol Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-220598","article-title":"Cerebrospinal fluid sTREM2 in Alzheimer\u2019s disease is associated with both amyloid and tau pathologies but not with cognitive status","volume":"90","author":"Li TR","year":"2022","unstructured":"Li TR, Lyu DY, Liu FQ. Cerebrospinal fluid sTREM2 in Alzheimer\u2019s disease is associated with both amyloid and tau pathologies but not with cognitive status. J Alzheimers Dis. 2022, 90:1123-38. 10.3233\/JAD-220598","journal-title":"J Alzheimers Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcad286","article-title":"sTREM2 is associated with attenuated tau aggregate accumulation in the presence of amyloid-\u03b2 pathology","volume":"5","author":"Nabizadeh F","year":"2023","unstructured":"Nabizadeh F. sTREM2 is associated with attenuated tau aggregate accumulation in the presence of amyloid-\u03b2 pathology. Brain Commun. 2023, 5:fcad286. 10.1093\/braincomms\/fcad286","journal-title":"Brain Commun"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-023-02962-z","article-title":"14-3-3 \u03b6\/\u03b4-reported early synaptic injury in Alzheimer's disease is independently mediated by sTREM2","volume":"20","author":"Woo MS","year":"2023","unstructured":"Woo MS, Nilsson J, Therriault J, et al.. 14-3-3 \u03b6\/\u03b4-reported early synaptic injury in Alzheimer's disease is independently mediated by sTREM2. J Neuroinflammation. 2023, 20:278. 10.1186\/s12974-023-02962-z","journal-title":"J Neuroinflammation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-66211-w","article-title":"Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study","volume":"14","author":"Nabizadeh F","year":"2024","unstructured":"Nabizadeh F, Seyedmirzaei H, Karami S. Neuroimaging biomarkers and CSF sTREM2 levels in Alzheimer's disease: a longitudinal study. Sci Rep. 2024, 14:15318. 10.1038\/s41598-024-66211-w","journal-title":"Sci Rep"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01506-8","article-title":"The longitudinal trajectory of CSF sTREM2: the Alzheimer's disease neuroimaging initiative","volume":"16","author":"Wang Y","year":"2024","unstructured":"Wang Y, Ye M, Ji Q, Liu Q, Xu X, Zhan Y. The longitudinal trajectory of CSF sTREM2: the Alzheimer's disease neuroimaging initiative. Alzheimers Res Ther. 2024, 16:138. 10.1186\/s13195-024-01506-8","journal-title":"Alzheimers Res Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/alz.092410","article-title":"CSF sTREM2 is associated with neuroprotective microglial states early in Alzheimer\u2019s disease and deleterious effects later in the disease trajectory","volume":"20","author":"Crook H","year":"2024","unstructured":"Crook H, Wahdan M, Tuil ME, Livingston NR, Raza S, Nowell J, Edison P. CSF sTREM2 is associated with neuroprotective microglial states early in Alzheimer\u2019s disease and deleterious effects later in the disease trajectory. Alzheimers Dement. 2024, 20:092410. 10.1002\/alz.092410","journal-title":"Alzheimers Dement"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13862","article-title":"CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease","volume":"20","author":"Warmenhoven N","year":"2024","unstructured":"Warmenhoven N, S\u00e1nchez-Benavides G, Gonz\u00e1lez-Escalante A, et al.. CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease. Alzheimers Dement. 2024, 20:5819-32. 10.1002\/alz.13862","journal-title":"Alzheimers Dement"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-022-01716-2","article-title":"Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer's disease","volume":"27","author":"Ferrari-Souza JP","year":"2022","unstructured":"Ferrari-Souza JP, Ferreira PC, Bellaver B, et al.. Astrocyte biomarker signatures of amyloid-\u03b2 and tau pathologies in Alzheimer's disease. Mol Psychiatry. 2022, 27:4781-9. 10.1038\/s41380-022-01716-2","journal-title":"Mol Psychiatry"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13450","article-title":"Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression","volume":"20","author":"Pelkmans W","year":"2024","unstructured":"Pelkmans W, Shekari M, Brugulat-Serrat A, et al.. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer's disease progression. Alzheimers Dement. 2024, 20:483-93. 10.1002\/alz.13450","journal-title":"Alzheimers Dement"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208075","article-title":"Association of plasma YKL-40 with MRI, CSF, and cognitive markers of brain health and dementia","volume":"102","author":"Pase MP","year":"2024","unstructured":"Pase MP, Himali JJ, Puerta R, et al.. Association of plasma YKL-40 with MRI, CSF, and cognitive markers of brain health and dementia. Neurology. 2024, 102:e208075. 10.1212\/WNL.0000000000208075","journal-title":"Neurology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.725511","article-title":"Serum amyloid biomarkers, tau protein and YKL-40 utility in detection, differential diagnosing, and monitoring of dementia","volume":"12","author":"Wilczy\u0144ska K","year":"2021","unstructured":"Wilczy\u0144ska K, Maciejczyk M, Zalewska A, Waszkiewicz N. Serum amyloid biomarkers, tau protein and YKL-40 utility in detection, differential diagnosing, and monitoring of dementia. Front Psychiatry. 2021, 12:725511. 10.3389\/fpsyt.2021.725511","journal-title":"Front Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2025.1630022","article-title":"Neuroinflammation-mediated YKL-40 correlates with tau pathology and predicts longitudinal cognitive impairment and brain atrophy in Alzheimer's disease, with hypertensive dependency","volume":"17","author":"Wang YY","year":"2025","unstructured":"Wang YY, Zhang M, Chen SJ, et al.. Neuroinflammation-mediated YKL-40 correlates with tau pathology and predicts longitudinal cognitive impairment and brain atrophy in Alzheimer's disease, with hypertensive dependency. Front Aging Neurosci. 2025, 17:1630022. 10.3389\/fnagi.2025.1630022","journal-title":"Front Aging Neurosci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201506123","article-title":"sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers","volume":"8","author":"Su\u00e1rez-Calvet M","year":"2016","unstructured":"Su\u00e1rez-Calvet M, Kleinberger G, Araque Caballero M\u00c1, et al.. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med. 2016, 8:466-76. 10.15252\/emmm.201506123","journal-title":"EMBO Mol Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav6221","article-title":"Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease","volume":"11","author":"Ewers M","year":"2019","unstructured":"Ewers M, Franzmeier N, Su\u00e1rez-Calvet M, et al.. Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimer's disease. Sci Transl Med. 2019, 11:6221. 10.1126\/scitranslmed.aav6221","journal-title":"Sci Transl Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006082","article-title":"CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease","volume":"91","author":"Janelidze S","year":"2018","unstructured":"Janelidze S, Mattsson N, Stomrud E, et al.. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology. 2018, 91:e867-77. 10.1212\/WNL.0000000000006082","journal-title":"Neurology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.08.025","article-title":"YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease","volume":"68","author":"Craig-Schapiro R","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, et al.. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry. 2010, 68:903-12. 10.1016\/j.biopsych.2010.08.025","journal-title":"Biol Psychiatry"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0893-7","article-title":"YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies","volume":"14","author":"Querol-Vilaseca M","year":"2017","unstructured":"Querol-Vilaseca M, Colom-Cadena M, Pegueroles J, et al.. YKL-40 (Chitinase 3-like I) is expressed in a subset of astrocytes in Alzheimer's disease and other tauopathies. J Neuroinflammation. 2017, 14:118. 10.1186\/s12974-017-0893-7","journal-title":"J Neuroinflammation"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aax3519","article-title":"Chi3l1\/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis","volume":"12","author":"Lananna BV","year":"2020","unstructured":"Lananna BV, McKee CA, King MW, et al.. Chi3l1\/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer's disease pathogenesis. Sci Transl Med. 2020, 12:3519. 10.1126\/scitranslmed.aax3519","journal-title":"Sci Transl Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/505452-association-of-strem2-and-ykl-40-with-alzheimers-disease-progression-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T13:37:31Z","timestamp":1782308251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/505452-association-of-strem2-and-ykl-40-with-alzheimers-disease-progression-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,24]]},"references-count":32,"URL":"https:\/\/doi.org\/10.7759\/cureus.111423","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,24]]}}}